Related Experiment Video

Updated: Mar 17, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?

Alessandra Modena1, Chiara Ciccarese1, Roberto Iacovelli1

  • 1Medical Oncology, University-Hospital of Verona , Verona, Italy.

Oncology Reviews
|July 30, 2016
PubMed

Insights

Metastatic castration-resistant prostate cancer (mCRPC) remains challenging. Immunotherapy targeting immune checkpoints like CTLA-4 and PD1/PD-L1 offers a promising strategy to enhance antitumor immunity and improve patient survival.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) requires novel therapeutic strategies for durable disease control.
  • Tumor-induced immunosuppression via immune checkpoints is a critical mechanism in prostate cancer (PC) progression.
  • PC patients are potential candidates for immunotherapy due to their immunosuppressive status.

Purpose of the Study:

  • To review the role of immune checkpoints, specifically CTLA-4 and PD1/PD-L1 pathways, in PC progression.
  • To summarize current clinical data and ongoing trials of immune checkpoint inhibitors in PC.
  • To discuss the need for biomarkers and explore novel immune checkpoint targets for PC therapy.

Main Methods:

  • Literature review of current knowledge on immune checkpoints in PC.
  • Analysis of clinical data and ongoing clinical trials for immune checkpoint inhibitors in PC.
  • Exploration of potential prognostic/predictive biomarkers and novel therapeutic targets.

Main Results:

  • Immune checkpoints, particularly CTLA-4 and PD1/PD-L1, play a significant role in mediating PC progression and immune evasion.
  • Immunotherapy targeting these checkpoints aims to restore anti-tumor immunity.
  • Several clinical trials are evaluating the efficacy of immune checkpoint inhibitors in PC patients.

Conclusions:

  • Blocking immune checkpoints represents a promising avenue for mCRPC treatment.
  • Identifying predictive and prognostic biomarkers is crucial for optimizing immunotherapy efficacy.
  • Further research into novel immune checkpoints may yield new therapeutic strategies for prostate cancer.
Keywords:
CTLA-4PD-1PD-L1Prostate cancerimmune checkpoint inhibitorsimmunotherapy

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K